3-(N-n-butyl-N-methylaminomethyl)pyridine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(N-n-butyl-N-methylaminomethyl)pyridine
• 英文别名: N-methyl-N-(pyridin-3-ylmethyl)butan-1-amine
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.277
• InChiKey: QKLBVCOXCYESHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲基丁胺 在 硼烷 、 三乙胺 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 3.0h， 生成 3-(N-n-butyl-N-methylaminomethyl)pyridine
  参考文献：
  名称：

  Pyrrolidine-modified and 6-substituted analogs of nicotine: A structure—affinity investigation

  摘要：

  Because the structural requirements for the binding of nicotine to central nicotine receptors remain largely uninvestigated, we undertook a systematic investigation of pyrrolidine ring-opened analogs. This led to a subsequent investigation of related conformationally restricted derivatives of these analogs. The results are reported relative to the binding of several well-known and widely used nicotine receptor ligands. Although none of the ring-opened analogs binds with higher affinity than (-)nicotine (K-i = 2.3 nM), 3-(N-methyl-N-ethylaminomethyl)pyridine (12a; K-i = 28 nM) binds with significant affinity. A conformationally restricted analog of 12a, N-methyl [2,7]naphthyridine 30b (K-i = 18 nM), binds with similar affinity. 6-Substitution of 12a and racemic nicotine seems to be tolerated when the substituent is halogen or methyl. In functional studies (hypolocomotion and antinociception in mice; stimulus generalization in nicotine-trained rats) 30b retains nicotine-like properties. Several of the 6-substituted compounds were 2 to 20 times more potent than (+/-)nicotine. Although the intact pyrrolidine ring of nicotine appears important for optimal affinity, its pre presence is not an absolute requirement for activity, and 6-position substitution of the pyridine nucleus can influence both binding and functional activity.

  DOI：

  10.1016/s0223-5234(97)89850-9

文献信息

• Benzimidazole derivatives and their use as a medicament
  申请人：Poitout Lydie

  公开号：US20090170922A1

  公开（公告）日：2009-07-02

  A subject of the present application is new benzimidazole derivatives of formula in which A, Y, R 1 , R 2 , R 3 and R 4 represent different variable groups. These products have an antagonist activity of GnRH (Gonadotropin-Releasing Hormone). The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.

  本申请的主题是公式中A、Y、R1、R2、R3和R4代表不同变量基团的新苯并咪唑衍生物。这些产物具有GnRH（促性腺激素释放激素）的拮抗活性。本发明还涉及含有所述产物的制药组合物及其用于制备药物的用途。
• Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders
  申请人：Unett David J.

  公开号：US20110177612A1

  公开（公告）日：2011-07-21

  The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
• US7495110B2
  申请人：——

  公开号：US7495110B2

  公开（公告）日：2009-02-24
• US7829298B2
  申请人：——

  公开号：US7829298B2

  公开（公告）日：2010-11-09
• US8236965B2
  申请人：——

  公开号：US8236965B2

  公开（公告）日：2012-08-07